🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan flag Japan · Delayed Price · Currency is JPY
2,056.00
-7.00 (-0.34%)
Nov 18, 2026, 3:30 PM JST

Santen Pharmaceutical Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
297,034291,624300,004301,965279,037266,257
Revenue Growth
1.91%-2.79%-0.65%8.22%4.80%6.67%
Cost of Revenue
121,783121,881128,977123,256112,950109,671
Gross Profit
175,251169,743171,027178,709166,087156,586
Selling, General & Admin
88,84184,53883,29986,880134,072120,610
Research & Development
26,14226,18524,10325,416--
Other Operating Expenses
-938-1,0091,638-282-3,285101
Operating Expenses
127,531123,519122,732126,524130,787120,711
Operating Income
47,72046,22448,29552,18535,30035,875
Interest Expense
-1,308-1,391-1,083-831-476-249
Interest & Investment Income
2,0881,4431,6231,2621,0861,063
Earnings From Equity Investments
---685-7,575-2,362-1,604
Currency Exchange Gain (Loss)
-495-4951,651-121-663-959
Other Non Operating Income (Expenses)
11911815-198-118371
EBT Excluding Unusual Items
48,12445,89949,81644,72232,76734,497
Merger & Restructuring Charges
----5,829-3,225-
Gain (Loss) on Sale of Investments
5,6385,638-708-1,046-228800
Gain (Loss) on Sale of Assets
-297-297-286738-554412
Asset Writedown
-3,798-3,798-1,302-7,547-34,508245
Legal Settlements
----410-51-338
Other Unusual Items
---39-755--
Pretax Income
49,66747,44247,48129,873-5,79935,616
Income Tax Expense
10,4829,88111,6283,1719,1848,427
Earnings From Continuing Operations
39,18537,56135,85326,702-14,98327,189
Minority Interest in Earnings
-309-192403-603529
Net Income
38,87637,36936,25626,642-14,94827,218
Preferred Dividends & Other Adjustments
499876
Net Income to Common
38,87237,36036,24726,634-14,95527,212
Net Income Growth
23.74%3.07%36.09%--298.65%
Shares Outstanding (Basic)
322328349367387400
Shares Outstanding (Diluted)
322328350368387400
Shares Change
-4.91%-6.10%-5.01%-4.98%-3.26%0.02%
EPS (Basic)
120.91114.03103.9872.59-38.6068.07
EPS (Diluted)
120.65113.80103.6872.37-38.6067.97
EPS Growth
30.10%9.76%43.26%--298.44%

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
41,30536,65654,26663,33019,87028,699
Free Cash Flow Per Share
128.18111.63155.18172.0351.2971.67
Dividend Per Share
19.00038.00036.00033.00032.00032.000
Dividend Growth
-50.00%5.56%9.09%3.13%0%14.29%
Gross Margin
59.00%58.21%57.01%59.18%59.52%58.81%
Operating Margin
16.07%15.85%16.10%17.28%12.65%13.47%
Profit Margin
13.09%12.81%12.08%8.82%-5.36%10.22%
Free Cash Flow Margin
13.91%12.57%18.09%20.97%7.12%10.78%
EBITDA
65,83964,58266,24370,36352,54952,930
EBITDA Margin
22.17%22.15%22.08%23.30%18.83%19.88%
D&A For EBITDA
18,11918,35817,94818,17817,24917,055
EBIT
47,72046,22448,29552,18535,30035,875
EBIT Margin
16.07%15.85%16.10%17.28%12.65%13.47%
Effective Tax Rate
21.11%20.83%24.49%10.62%-23.66%
Advertising Expenses
-14,11813,31018,278--